Tab Title Description
The purpose of the registry is to evaluate real-world safety, efficacy, and patient reported outcomes among participants receiving Vanquish Water Vapor Ablation System therapy (Vanquish Therapy). This includes longitudinal assessment of patients who have received or will receive the therapy one or multiple times as part of routine clinical care and encompasses those who completed a company-sponsored Vanquish therapy study (as applicable).
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
Inclusion Criteria:* Candidate for Vanquish therapy per physician discretion or participant has completed a company-sponsored Vanquish therapy study.* Participant is willing and able to provide written informed consent.Exclusion Criteria:* Contraindications per the Vanquish IFU* Previously participated in VAPOR 2 study and is not planning to receive further Vanquish therapy.
Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.
Mayo Clinic principal investigator
Daniel Frendl, M.D., Ph.D.
Contact us for the latest status
Cancer Center Clinical Trials Referral Office
(855) 776-0015